CDK4 and head and neck squamous cell carcinoma: Because of this, CDK4/6 inhibitors have been explored as a means to inhibit this pathway, but thus far with limited success with Abemaciclib demonstrating no objective response in patients with HNSCC who had progressed through 1st line chemotherapy with Cetuximab [50].